Pinealon for neuroprotection

What the evidence says

Evidence tier: Weak anecdotal. Anecdotal reports exist but without strong mechanistic backing for this specific use.

• Animal models showed reduced oxidative damage in brain tissue (Russian work, Arutjunyan et al., 2013).
• Often stacked with Epitalon and Cerebrolysin in longevity protocols.
• There is no human dementia-prevention data for Pinealon - the claim is mechanistic, not proven.

Protocol notes

5-10mg subcutaneous daily for 10 days, repeated every 4-6 months. Not a substitute for proven dementia-prevention protocols.

Always with a sports-medicine doctor, telehealth provider, or specialist sign-off. Self-experimenting on injection schedules without clinical input is the most common way people waste money and get hurt.

What to skip

• Vendors without a Certificate of Analysis (COA). Random gym-bro vendors with no third-party testing. The peptide market has a quality-control problem; the answer is COA per peptide, every time.
• Pre-mixed blends from non-pharmacy sources. Compounding pharmacies that produce pre-mixed combinations with COAs are fine. Random vendor "stack vials" are not.
• Massively over-dosed protocols. More is rarely better with peptides. Receptor saturation is real. Stick to evidence-based dosing.

Where to go next

• Full Pinealon directory entry - status, sourcing, studies, what to skip
• What are peptides - if you skipped the foundation
• How peptides actually work - mechanism in plain English
• The Tier List - which ones to take seriously
• Subscribe to the dispatch

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read. Broken down for normal humans.

-> Subscribe free